cathepsin L pseudogene 4Genealiases: CTSL1P4 · CTSLL4 · bA564C4.3
Q-omics provides the consensus-scored CTSLP4 profile across patient tissues and cancer cell-line models. CTSLP4 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, CTSLP4 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, CTSLP4 RNA expression shows 5,531 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, KIRC, and TGCT as cancer lineages where CTSLP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTSLP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTSLP4 survival associations across molecular data types. CTSLP4 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTSLP4 RNA expression–survival associations across cancer types. High CTSLP4 expression shows unfavorable associations in COAD, DLBC, UCEC, PAAD, LUAD and LUSC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for CTSLP4 RNA expression.
This table summarizes CTSLP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CTSLP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTSLP4 shows lower tumor expression in KIRC, THCA, KICH and KIRP and higher tumor expression in HNSC and LIHC. The KIRC box plot shows higher CTSLP4 RNA expression in normal versus tumor tissue (log2 FC = −0.047, t-test p < 0.001).
This table shows molecular features associated with CTSLP4 in patient tissues and cancer cell lines. In patient samples, CTSLP4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
